SUMMARY
Once more, the European Society for Medical Oncology (ESMO) dedicated a session to haematological malignancies during its last meeting in October 2023. This session revealed novel immunotherapeutic strategies, such as activating γ9δ2 T cells to treat haematological cancers and using trifunctional natural killer (NK) cell engagers to eliminate CD123+ tumour cells. Additionally, promising results were observed with the combination of toripalimab and radiotherapy in treating extranodal NK/T cell lymphoma. Furthermore, genetic analyses identified genetic alterations with prognostic value for anti-PD-1 therapy in peripheral T-cell lymphomas (PTCL). Finally, a large cohort study examined treatment outcomes in primary ocular adnexal MALT lymphoma (POAML) patients.
(BELG J HEMATOL 2024;15(2):62–5)
